![]() An improvement in hemostasis has not been established. This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. See full prescribing information for complete boxed warningĪNDEXXA is indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed. Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Ischemic events, including myocardial infarction and ischemic stroke Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including: (5.1)Īrterial and venous thromboembolic events WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |